NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Turn Biotechnologies

Private
Mountain View, CaliforniaHealthcare & Life Sciences

Last Round

M&A

May 21, 2026

Est. Valuation

$59M

Total Funding Raised

$30.1M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Turn Biotechnologies is a biotechnology company that develops mRNA-based therapies to repair and rejuvenate tissue at the cellular level by reprogramming the epigenome.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

epigenetic reprogramminglipid nanoparticleLNPlongevity biotechmRNA therapeuticsrejuvenation therapyage-related diseasedrug delivery platformpreclinical researchbiotech licensingcellular reprogramminganti-agingrestorative medicinebiotech R&D

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Turn Biotechnologies Comparables

Compare Turn Biotechnologies with similar companies based on industry and business-model similarity.

Turn Biotechnologies comparables — related companies by embedding similarity
CompanySimilarityMarket Cap

View Full Comparables Set

Access detailed peer comparisons, similarity scores, and market data.

Turn Biotechnologies Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
M&AMay 21, 2026
Series ASep 6, 2023
GrantJul 21, 2022
SeedApr 11, 2022
SeedApr 28, 2021

Key People

Founding team and executive leadership

Sergio Ruiz

Co-Founder Chief Operating Officer

Founding Team

Ric Peterson

Chief Financial Officer

Executive Team

Turn Biotechnologies Investors

Notable investors and investment history

Turn Biotechnologies investors
InvestorRounds
Khosla VenturesSeed, Series A
VitaDAOGrant
LongeVCSeed
ThreeD CapitalSeed
Vitality Healthspan FoundationSeed
Astellas Venture ManagementSeries A, Seed
Shanda GroupSeed

Market signals

Structured signals derived from secondary market and firmographic data.

  • Sep 30, 2025

    Select assets acquired for $300M, anchored by pharma partnership.

Turn Biotechnologies Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Turn Biotechnologies Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Turn Biotechnologies's valuation, stock price, and market status.

Firmographic Details

HeadquartersMountain View, California
Employee Range14
Year Founded2018
Last FundingMay 21, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.